REPL

Replimune GroupC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

Materiality

84.25

distress

Source

External coverage

Decided

2026-05-30

Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.

Replimune said it will lay off staff after the FDA rejected its cancer therapy again; the stock fell 64%, signaling an acute company-specific regulatory and financing setback.

View event details

Sentiment decomposition

-0.8

30-day score

Company-55%

Macro-30%

Pulse-15%

The 30-day sentiment score is a decayed blend of Company, Macro, and Pulse components.

Recent headlines

Headline

Time

Relevance

REPL Stock Shot Up 80% Today Whats The Deal With FDA?

2026-05-29

64%

External coverage

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

2026-05-29

23%

External coverage

Replimune Gets Third Try at FDA Approval After Makary Departure

2026-05-29

23%

External coverage

Replimune melanoma therapy rejected by FDA, shares plunge

2026-04-13

23%

External coverage

FDA issues complete response letter to Replimunes RP1 for melanoma

2026-04-13

23%

External coverage

Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgraded

2026-04-13

55%

External coverage

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

2026-04-10

23%

External coverage

As of 2026-05-30 • Updated scheduledSource: News desk